S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
New CBOE “special perk” helps traders target income every weekend (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
New CBOE “special perk” helps traders target income every weekend (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
New CBOE “special perk” helps traders target income every weekend (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
New CBOE “special perk” helps traders target income every weekend (Ad)
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
New CBOE “special perk” helps traders target income every weekend (Ad)
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod

Sarepta Therapeutics Stock Price, News & Analysis (NASDAQ:SRPT)

$87.03
-1.38 (-1.56%)
(As of 12/8/2023 ET)
Compare
Today's Range
$87.01
$89.65
50-Day Range
$67.31
$124.76
52-Week Range
$55.25
$159.89
Volume
614,084 shs
Average Volume
1.08 million shs
Market Capitalization
$8.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$153.10

Sarepta Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
75.9% Upside
$153.10 Price Target
Short Interest
Healthy
4.54% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
1.35mentions of Sarepta Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$5.94 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($6.90) to $0.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.90 out of 5 stars

Medical Sector

29th out of 942 stocks

Pharmaceutical Preparations Industry

9th out of 445 stocks


SRPT stock logo

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

SRPT Stock Price History

SRPT Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Sarepta Therapeutics Inc SRPT
11 Best Upside Stocks To Buy Right Now
Big Players' Recent Trades in SRPT Options
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Is Sarepta Therapeutics Stock a Bad-News Buy?
1 Gene Therapy Stock to Buy and Hold for the Long Haul
Sarepta (SRPT) Q3 Loss Narrower Than Expected, Sales Beat
Sarepta Therapeutics Q3 Earnings Summary
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,162
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$153.10
High Stock Price Target
$224.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+75.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Net Income
$-703,490,000.00
Pretax Margin
-59.89%

Debt

Sales & Book Value

Annual Sales
$933.01 million
Book Value
$4.39 per share

Miscellaneous

Free Float
86,625,000
Market Cap
$8.14 billion
Optionable
Optionable
Beta
1.02

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Douglas S. Ingram Esq.Mr. Douglas S. Ingram Esq. (Age 60)
    President, CEO & Director
    Comp: $1.62M
  • Mr. Ian Michael Estepan (Age 47)
    Executive VP & CFO
    Comp: $917.53k
  • Dr. Louise R. Rodino-Klapac Ph.D. (Age 45)
    Executive VP, Chief Scientific Officer and Head of Research & Development
    Comp: $1.04M
  • Mr. Ryan E. Brown J.D. (Age 45)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $823.36k
  • Mr. Bilal Arif (Age 51)
    Executive VP & Chief Technical Operations Officer
  • Ms. Francesca T. Nolan
    Executive Director of Investor Relations and Corporate Communications
  • Ms. Alison Nasisi
    Executive VP & Chief People Officer
  • Dr. Diane L. Berry Ph.D.
    Executive VP and Chief of Global Policy & Advocacy Officer
  • Mr. Dallan Murray
    Executive VP & Chief Customer Officer
  • Mr. Will Tilton
    Senior VP, Head of Strategy & Chief of Staff














SRPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price target for 2024?

18 equities research analysts have issued 1 year target prices for Sarepta Therapeutics' stock. Their SRPT share price targets range from $40.00 to $224.00. On average, they anticipate the company's share price to reach $153.10 in the next year. This suggests a possible upside of 75.9% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2023?

Sarepta Therapeutics' stock was trading at $129.58 on January 1st, 2023. Since then, SRPT shares have decreased by 32.8% and is now trading at $87.03.
View the best growth stocks for 2023 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.37 EPS for the quarter, beating the consensus estimate of ($1.63) by $2.00. The biotechnology company had revenue of $331.80 million for the quarter, compared to analysts' expectations of $285.33 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 46.23% and a negative net margin of 62.52%. The firm's revenue for the quarter was up 44.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.94) EPS.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (4.18%), Deutsche Bank AG (1.14%), Deutsche Bank AG (1.14%), Federated Hermes Inc. (1.03%), Westfield Capital Management Co. LP (0.86%) and Charles Schwab Investment Management Inc. (0.60%). Insiders that own company stock include Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
This page (NASDAQ:SRPT) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -